Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) (NCT01940796)
This research study is trying to determine the safest dose of brentuximab vedotin (also known as SGN-035) that can be given to patients with chronic Graft-vs.-Host Disease (GVHD) and see if chronic GVHD improves.
- Condition: Graft vs. Host Disease (GVHD)
- Phase: I
- Estimated Enrollment: 40
- Start: October 2013
- Estimated Completion: September 2019
- Last verified: November 2014
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.